{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:03:47Z","timestamp":1779793427624,"version":"3.53.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"DOI":"10.7759\/cureus.109667","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:24:56Z","timestamp":1779791096000},"source":"Crossref","is-referenced-by-count":0,"title":["Wild-Type Transthyretin Cardiac Amyloidosis Presenting As Progressive Heart Failure and Conduction Disease Despite Guideline-Directed Medical Therapy"],"prefix":"10.7759","author":[{"given":"Srivane","family":"Richard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameeksha","family":"Devkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Graham-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al.. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023, 81:1076-126. 10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg FL","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024, 331:778-91. 10.1001\/jama.2024.0442","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815","article-title":"Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial)","volume":"10","author":"Maurer MS","year":"2017","unstructured":"Maurer MS, Elliott P, Merlini G, et al.. Design and rationale of the phase 3 ATTR-ACT clinical trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. 2017, 10:003815. 10.1161\/CIRCHEARTFAILURE.116.003815","journal-title":"Circ Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk RH","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016, 68:1323-41. 10.1016\/j.jacc.2016.06.053","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2022.07.008","article-title":"Multi-imaging characterization of cardiac phenotype in different types of amyloidosis","volume":"16","author":"Ioannou A","year":"2023","unstructured":"Ioannou A, Patel RK, Razvi Y, et al.. Multi-imaging characterization of cardiac phenotype in different types of amyloidosis. JACC Cardiovasc Imaging. 2023, 16:464-77. 10.1016\/j.jcmg.2022.07.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.17925\/HI.2024.18.1.5","article-title":"Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis","volume":"18","author":"Ioannou A","year":"2024","unstructured":"Ioannou A. Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis. Heart Int. 2024, 18:30-7. 10.17925\/HI.2024.18.1.5","journal-title":"Heart Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102172","article-title":"Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"63","author":"Wang J","year":"2023","unstructured":"Wang J, Chen H, Tang Z, et al.. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine. 2023, 63:102172. 10.1016\/j.eclinm.2023.102172","journal-title":"EClinicalMedicine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 73:2872-91. 10.1016\/j.jacc.2019.04.003","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.060061","article-title":"Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation","volume":"126","author":"Lane DA","year":"2012","unstructured":"Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012, 126:860-5. 10.1161\/CIRCULATIONAHA.111.060061","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478615-wild-type-transthyretin-cardiac-amyloidosis-presenting-as-progressive-heart-failure-and-conduction-disease-despite-guideline-directed-medical-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:24:57Z","timestamp":1779791097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478615-wild-type-transthyretin-cardiac-amyloidosis-presenting-as-progressive-heart-failure-and-conduction-disease-despite-guideline-directed-medical-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.109667","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}